Table 1.
Comparative characteristics of CD20XCD3 BsAb currently in development
| Product name | Schematic depiction | Format | Technology | CD20:CD3 ratio | CD3 clone | CD20 clone | Fc silencing mutations∗ |
|---|---|---|---|---|---|---|---|
| Mosunetuzumab18 |  | IgG1 | Knobs-into-holes (different Fabs) | 1:1 | UCHT1v9 (CD3δε) | 2H7 (type 1 epitope, identical to rituximab) | N297G (no FcγR binding) |
| Glofitamab15 |  | IgG1 | Head-to-tail fusion | 2:1 | SP34-der.(CD3ε) | By-L1 (type 2 epitope, identical to obinutuzumab) | IgG1-P329G-LALA (no FcγR binding) |
| Epcoritamab16 |  | IgG1 | Controlled Fab-arm exchange | 1:1 | huCACAO (SP34-der.)(CD3ε) | 7D8 (type 1 epitope, shared by ofatumomab) | L234F,L235E,D265A (no FcγR,C1q binding) |
| Odronexamab17 |  | IgG4 | Heavy chains with different affinity | 1:1 | REG1250 (CD3δε) | 3B9-10 (type 1 epitope, shared by ofatumomab) | Modified IgG4 (no FcγRIII binding) |
| Plamotamab90 |  | IgG1 | Fab-Fc x scFv-Fc | 1:1 | α-CD3_H1.30 (SP34-der.)(CD3ε) | C2B8_H1_L1 (type 1 epitope, shared by rituximab) | G236R, L328R (no FcγR binding) |
| IgM 232319 |  | IgM | IgM + modified J chain | 10:1 | Not reported | Not reported | No |
| Product name | Schematic depiction | Format | Technology | CD20:CD3 ratio | CD3 clone | CD20 clone | Fc silencing mutations∗ |
|---|---|---|---|---|---|---|---|
| Mosunetuzumab18 | | IgG1 | Knobs-into-holes (different Fabs) | 1:1 | UCHT1v9 (CD3δε) | 2H7 (type 1 epitope, identical to rituximab) | N297G (no FcγR binding) |
| Glofitamab15 | | IgG1 | Head-to-tail fusion | 2:1 | SP34-der.(CD3ε) | By-L1 (type 2 epitope, identical to obinutuzumab) | IgG1-P329G-LALA (no FcγR binding) |
| Epcoritamab16 | | IgG1 | Controlled Fab-arm exchange | 1:1 | huCACAO (SP34-der.)(CD3ε) | 7D8 (type 1 epitope, shared by ofatumomab) | L234F,L235E,D265A (no FcγR,C1q binding) |
| Odronexamab17 | | IgG4 | Heavy chains with different affinity | 1:1 | REG1250 (CD3δε) | 3B9-10 (type 1 epitope, shared by ofatumomab) | Modified IgG4 (no FcγRIII binding) |
| Plamotamab90 | | IgG1 | Fab-Fc x scFv-Fc | 1:1 | α-CD3_H1.30 (SP34-der.)(CD3ε) | C2B8_H1_L1 (type 1 epitope, shared by rituximab) | G236R, L328R (no FcγR binding) |
| IgM 232319 | | IgM | IgM + modified J chain | 10:1 | Not reported | Not reported | No |
∗
These Fc-silencing mutations do not abolish the binding of BsAb to neonatal FcR.